688289 Sansure Biotech Inc.
- 18.30
- -0.24-1.29%
Sansure Biotech Inc. News
Shengxiang Biology (688289): Rapid development of respiratory testing business drives both revenue and profitability
Shengxiang Biology (688289): Breathing brightly, thick, thin hair
Shengxiang Biology (688289): Significant release of respiratory joint testing products explores a new blue ocean in the home market
Shengxiang Biology (688289): Demand for respiratory products increased, revenue from conventional reagents doubled in 2023
Shengxiang Biology (688289): The performance report is in line with expectations, leading molecular diagnostics companies are growing rapidly
Shengxiang Biology (688289): Deeply involved in the field of molecular diagnosis platformization can be expected to enter a high growth trajectory
Shengxiang Biotech (688289): Rapid growth in conventional business, continuous improvement in costs
Shengxiang Biology (688289): Focus on independent innovation and R&D to build an ecological industry chain for in vitro diagnosis
Shengxiang Biology (688289): Molecular Leaders Poised to Deepen Global Markets
Shengxiang Biology (688289): Revenue increased rapidly by 33% and launched a variety of new products including six joint tests for respiratory viruses
Shengxiang Biology (688289) Annual Review Report: Performance Meets Expectations and Optimistic About the Company's International Platform Type
Shengxiang Biology (688289): Strategic production lines provide impetus for growth, continued strong demand for COVID-19 nucleic acid testing led to a 24% increase in Q1 revenue
Shengxiang Biology (688289): Towards a Platform, Waiting for Flowers to Bloom
Shengxiang Biology (688289): The COVID-19 reagent price correction performance was under pressure in the short term, and traditional superior reagents achieved a rapid increase of 134%
Shengxiang Biology (688289): high growth of conventional business continues to promote internationalization
Comments on Shengxiang Biology (688289) 2021: anti-epidemic dividend still exists and development achievements have been achieved.
Comments on the 2020 Annual report of Shengxiang Biology (688289): the advantage of epidemic resistance is being transformed into long-term growth kinetic energy.
Shengxiang Biological (688289) 2020 performance Forecast Review: maintain high growth throughout the year and be optimistic about the great-leap-forward development boosted by the epidemic
Shengxiang Biology (688289) in-depth report: gene testing universal benefits embark on a new journey of development under the opportunity of epidemic situation
Shengxiang Bio (688289): COVID-19 testing helps overseas market performance is expected to continue to grow at a high speed throughout the year
Analysis
Price Target
No Data
